2023 World Conference on Lung Cancer (Posters)-EP11.03. Multi-Institutional Retrospective Study for the Efficacy of ICIs plus Platinum-Based Chemotherapy for EGFR Mutated NSCLC

EP11.03. Multi-Institutional Retrospective Study for the Efficacy of ICIs plus Platinum-Based Chemotherapy for EGFR Mutated NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This study examined the effectiveness of combining immune checkpoint inhibitors (ICIs) with platinum-based chemotherapy in patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer. The researchers conducted a retrospective analysis of patients treated with either the combination therapy (Chemo-ICI) or platinum-based chemotherapy alone (Chemo) after failing EGFR tyrosine kinase inhibitors (TKIs). <br /><br />The results showed that the addition of ICIs to chemotherapy did not significantly prolong progression-free survival (PFS) or overall survival (OS) compared to chemotherapy alone. The median PFS was 6.6 months in the Chemo-ICI group and 6.2 months in the Chemo group, with no significant difference between the two. Similarly, the median OS was 26.4 months in the Chemo-ICI group and 23.7 months in the Chemo group, again with no significant difference. <br /><br />However, the response rate was higher in the Chemo-ICI group compared to the Chemo group (51.4% versus 27.4%, p<0.02). Additional analysis showed that postoperative recurrence was significantly associated with better PFS, while the absence of liver metastases tended to be associated with better PFS. <br /><br />In an exploratory analysis, the researchers compared survival outcomes in patients treated with the IMpower150 regimen (n=21) and the non-IMpower150 regimen (n=15) within the Chemo-ICI group. There was no significant difference in median OS between the two groups.<br /><br />Overall, the study concluded that the addition of ICIs to platinum-based chemotherapy did not provide a significant survival benefit in patients with EGFR-mutated non-small cell lung cancer. Furthermore, there were no significant differences in survival outcomes based on the specific Chemo-ICI regimen used.<br /><br />Keywords: EGFR mutated NSCLC, ICIs, retrospective study.

Asset Subtitle

Shunichi Kataoka

Meta Tag

Speaker Shunichi Kataoka

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

immune checkpoint inhibitors

platinum-based chemotherapy

epidermal growth factor receptor

EGFR mutated non-small cell lung cancer

retrospective analysis

Chemo-ICI

Chemo

progression-free survival

overall survival

response rate